The Green Room: A Podcast from Obstetrics & Gynecology August 2024: Gynecology
Jul 18, 2024
Dr. Andrea Ries Thurman, a board-certified OBGYN and medical director at Dare Bioscience, discusses groundbreaking research on female sexual health. She highlights the promising results of a study on topical sildenafil cream for Female Sexual Arousal Disorder, emphasizing its potential to improve women's lives. The conversation also touches on the challenges faced in treating this condition, the emotional impacts on patients, and the critical need for more research and awareness in women's sexual health.
AI Snips
Chapters
Transcript
Episode notes
Unmet Need In FSAD Treatment
- Female sexual arousal disorder (FSAD) lacks FDA-approved treatments despite significant patient need.
- Dr. Andrea Ries Thurman emphasized this therapeutic gap and the desire for safe, effective options.
First At-Home Sildenafil Cream Trial
- The trial tested a topical sildenafil cream used at home over 12 weeks in premenopausal women with FSAD.
- Isabella Johnson framed the study as phase 2B and the first at-home randomized trial for this product.
Recruitment Hampered By Partner Consent
- Recruitment drew thousands of clicks but many women declined due to required partner enrollment and contact.
- Dr. Andrea Ries Thurman described how the partner-consent safety requirement hindered enrollment and was later changed.